Hall, Deborah A.
Robertson, Erin
Shelton, Annie L.
Losh, Molly C.
Mila, Montserrat
Moreno, Esther Granell
Gomez-Anson, Beatriz
Martínez-Cerdeño, Verónica
Grigsby, Jim
Lozano, Reymundo
Hagerman, Randi
Maria, Lorena Santa
Berry-Kravis, Elizabeth
O’Keefe, Joan A.
Funding for this research was provided by:
National Institutes of Health (R01NS082416, R01MH091131, R01DC010191, R01HD032071, GM082773)
Fondo de Investigaciones Sanitarias (FIS PI 0770 (BGA))
National Institute of Mental Health (NIMH094681)
Strategic Initiative Review Committee of the University of Colorado School of Medicine
Australian Postgraduate Award
National Fragile X Foundation Fellowship award
Rush University Translational Sciences Consortium Award
Friedman Brain Institute and Seaver Faculty Scholar
Article History
First Online: 10 June 2016
Compliance with Ethical Standards
:
: Randi Hagerman has received funding from Novartis, Roche, Neuren, and Alcobra for treatment trials in fragile X syndrome (FXS). She has also consulted with Roche/Genentech, Alcobra and Novartis regarding treatment trials in FXS. Elizabeth Berry-Kravis has received funding from Neuren and Alcobra to carry out treatment studies in patients with FXS. She has also received funding from Vtesse to carry out a clinical trial in Niemann-Pick type C. She has also consulted with Neuren, Alcobra, and Neurotrope regarding treatment studies in patients with FXS. Deborah Hall has received research funds from NINDS, Shapiro Foundation, National Parkinson Disease Foundation, Pfizer, and Neurocrine. Dr. Lozano has consulted for Ambry genetics, Courtagen and ClearView Healthcare Partners. The authors declare that they have no conflict of interest.